drugset / Trial / NCT05749627
Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors
Recruiting
20 enrolled
The First Affiliated Hospital of Nanchang University
Shanghai Dengding BioAI Co. · collab
NaSingle-groupOpen-labelTreatment
Summary
In this study, the investigators provide a personalized tumor neoantigen peptide vaccine/neoantigen-based DC treatment to patients with advanced malignant solid tumors. The investigators observe the post-treatment tumor burden status, the immune response induced by immune preparations, and the prolongation of patient survival time, aiming to evaluate the effectiveness and safety of the neoantigen-based DC treatment.
Timeline
- Start
- 2023-04-01
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neoantigen Peptide Vaccine | Vaccine | — | — |
| Subject | Neoantigen-based DC immune preparation | Cell therapy | — | — |